ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Jnana Therapeutics has launched with $50 million in series A funding to discover small molecules that target a family of membrane proteins called solute carriers (SLCs). “Only a handful” of more than 400 SLC proteins have been tapped as drug targets, Jnana CEO Amir Nashat says. SLCs are important for transporting nutrients and drugs across cell membranes; Jnana’s first programs will focus on ones implicated in immuno-oncology, inflammation, and neurological disease. Jnana’s founders include Harvard University chemist Stuart Schreiber.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X